ライフサイエンスコーパス: RVFV

1 RVFV has a trisegmented single-stranded RNA (ssRNA) geno

2 RVFV has caused large, devastating periodic epizootics a

3 RVFV infection also elicited autophagy in mouse and huma

4 RVFV is a mosquito-borne bunyavirus that is endemic to A

5 RVFV is classified as a category A priority pathogen and

6 RVFV is listed as a select agent with significant potent

7 RVFV MP12-infected cells also displayed an S phase arres

8 RVFV NSm protein is the first identified Phlebovirus pro

9 RVFV virulence depends on the interferon antagonist non-

10 us challenge with the virulent Kenya-128B-15 RVFV strain.

11 ulent Rift Valley fever virus strain ZH-501 (RVFV ZH-501) at 126 days after vaccination were protecte

12 interferon (IFN-alpha) in sera, accumulated RVFV antigens in dendritic cells at the local draining l

13 es or antiviral agents with activity against RVFV, and details of its life cycle and interaction with

14 the antiviral activity of IFN-alpha against RVFV.

15 tibody and provides solid protection against RVFV challenge in the most susceptible natural target sp

16 hAdOx1, to develop a vaccine for use against RVFV in both livestock and humans.

17 esent study determined the 3' termini of all RVFV mRNAs.

18 In the past 15 years alone, RVFV caused tens of thousands of human cases, hundreds o

19 We established an RVFV T7 RNA polymerase-driven minigenome system in which

20 Unexpectedly, the coexpression of an RVFV nonstructural protein, NSs, with N and L proteins r

21 The discrimination of WNV and RVFV antigen detection in mixed Raman spectra was achiev

22 nes and diagnostics, since no effective anti-RVFV treatments are available for human use.

23 ceptor adaptor, MyD88, was required for anti-RVFV autophagy, revealing an evolutionarily conserved re

24 ination resulted in a rapid increase in anti-RVFV IgM (day 4) and IgG (day 7) titers.

25 downregulate PKR with similar efficiency as RVFV, while infection with the other phleboviruses-i.e.,

26 s, indicating that these viruses, as well as RVFV on certain cell types, employ additional unidentifi

27 ld-type infection, we utilized an attenuated RVFV lacking NSs to examine host responses following pri

28 to show that both pathogenic and attenuated RVFV strains require GAGs for efficient infection on som

29 munogenicity and efficacy of live-attenuated RVFV vaccine, which will lead to rational design of safe

30 Because RVFV cap-snatches in RNA granules, the increased level o

31 tion of the DNA damage signaling cascades by RVFV infection and found virally inducted phosphorylatio

32 cellular factors, and entry pathways used by RVFV and other members of the family Bunyaviridae remain

33 Clinically, RVFV induces a gamut of symptoms ranging from febrile il

34 Consequently, RVFV replication was severely reduced in Skp1-depleted c

35 species were exposed to aerosols containing RVFV.

36 viral responses are critical for controlling RVFV replication, but the roles of downstream adaptive i

37 Knockdown of VCP resulted in decreased RVFV replication, reduced Gn Golgi complex localization,

38 T16 selectively degrades 5'-TOP mRNAs during RVFV infection and this decay is triggered in response t

39 ite this, translational arrest occurs during RVFV infection by unknown mechanisms.

40 re, we investigated the role of PABP1 during RVFV infection of HeLa cells.

41 t mortality and more subtle pathology during RVFV infection.

42 st that production of the NSs protein during RVFV infection leads to sequestration of PABP1 in the nu

43 HIV, and MHV68 and acutely pathogenic EBOV, RVFV, RSSEV, and Nipah viruses under BSL4 conditions.

44 ism of PKR by NSs is essential for efficient RVFV replication in mammalian cells.

45 nization with ChAdOx1-GnGc vaccine, encoding RVFV envelope glycoproteins, elicits high-titre RVFV-neu

46 ila DDX17 (Rm62) in cells and flies enhanced RVFV infection.

47 p62, forming nuclear filaments and enhancing RVFV virulence.

48 However, at least filoviruses, RVFV, and CPXV are immune to its inhibitory effect.

49 428) phosphorylation was decreased following RVFV infection.

50 nalysis of the human host response following RVFV infection, which could give insight into novel host

51 In an effort to repurpose drugs for RVFV treatment, our previous studies screened a library

52 The implications of these findings for RVFV genome packaging and the potential to develop multi

53 of sorafenib, was found to be important for RVFV egress.

54 s (RVFV), thus providing an animal model for RVFV pathogenesis.

55 icial role of Wnt signaling was observed for RVFV, along with other disparate bunyaviruses, indicatin

56 The potential for RVFV introduction outside the area of endemicity highlig

57 To determine whether PABP1 was required for RVFV infection, we measured the production of nucleocaps

58 , indicating that PABP1 was not required for RVFV infection.

59 s used to identify host factors required for RVFV infection.

60 tible species, is an attractive strategy for RVFV.

61 sis and suggest that future therapeutics for RVFV hemorrhagic disease might target inhibition of cell

62 to the kinetics of antiviral protection from RVFV infection.

63 have recently reported novel next generation RVFV vaccines that are safe for use in pregnant and youn

64 However, RVFV NSs mRNA synthesis, but not N mRNA synthesis, was r

65 Human RVFV infections generally manifest as a self-limiting fe

66 tional design of safe and highly immunogenic RVFV vaccines for livestock and humans.

67 valuated the roles of B cells and T cells in RVFV pathogenesis.

68 s introduction of this virus could result in RVFV becoming endemic in North America.

69 Functional studies in RVFV-infected cells show that the OmegaXaV motif is requ

70 a shutoff of host cell protein synthesis in RVFV-infected cells.

71 but not the related helicase DDX5 increased RVFV replication in human cells.

72 ackaging of these RNAs to produce infectious RVFV.

73 rmacologic activation of autophagy inhibited RVFV infection in mammalian cells, including primary hep

74 e cellular target of sorafenib that inhibits RVFV propagation, so that this information can be used a

75 Instead, RVFV was introduced through ruminant trade and subsequen

76 e copackaging of the three genomic RNAs into RVFV particles.

77 esulted in the copackaging of both RNAs into RVFV-like particles, while replacing M RNA with M1 RNA,

78 In 2008 to 2009, a large RVFV outbreak was detected in Malagasy livestock and hum

79 Mice were protected from lethal RVFV challenge.

80 In Drosophila, Toll-7 limited RVFV replication and mortality through activation of aut

81 c pathogen that primarily affects livestock, RVFV can also cause lethal hemorrhagic fever and encepha

82 he pathogenesis in humans and livestock make RVFV a serious public health concern.

83 rtation from the East African mainland, nine RVFV whole genomic sequences were generated for viruses

84 The ability of RVFV to expand geographically outside sub-Saharan Africa

85 prevention of viremia, fever and absence of RVFV-associated histopathological lesions.

86 The intracellular accumulation of RVFV virions was also observed in cells transfected with

87 netics system to rescue infectious clones of RVFV MP-12 strain entirely from cDNA, the first for any

88 A key component of RVFV virulence is its ability to form nuclear filaments

89 g strategy for the prevention and control of RVFV infections in susceptible hosts.

90 CD4(+) T cells are critical determinants of RVFV pathogenesis and play an important role in preventi

91 We identified a stable core domain of RVFV NSs (residues 83-248), and solved its crystal struc

92 Marmosets were susceptible to lower doses of RVFV than AGM.

93 ed towards the broader infection dynamics of RVFV, because suitable host, vector and environmental co

94 the thymidine kinase gene, and expression of RVFV glycoproteins, Gn and Gc.

95 NSs protein, a major virulence factor of RVFV, inhibits host transcription including interferon (

96 lar localization and biological functions of RVFV NSs, and the co-expression of truncated NSs does no

97 e-sense viruses, the segmented RNA genome of RVFV is encapsidated by a nucleocapsid protein (N).

98 A hallmark of RVFV pathology is NSs filament formation in infected cel

99 In addition we demonstrate induction of RVFV-neutralizing antibody by ChAdOx1-GnGc vaccination i

100 es developed mild fevers after inhalation of RVFV, but no other clinical signs were noted and no maca

101 gether suggest that the primary mechanism of RVFV MP-12 uptake is dynamin-dependent, caveolin-1-media

102 To determine the cellular entry mechanism of RVFV, we used small-molecule inhibitors, RNA interferenc

103 nce for the importance of oligomerization of RVFV L protein for its polymerase activity.

104 three-dimensional structural organization of RVFV vaccine strain MP-12 by cryoelectron tomography.

105 aluated the infectivity and pathogenicity of RVFV in the common marmoset (Callithrix jacchus) by i.v.

106 ls of PABP1, we found that the percentage of RVFV N-positive cells was decreased in cell populations

107 We found that the overall percentage of RVFV N-positive cells was not changed by siRNA treatment

108 ticle aerosol challenge of 5 x 10(5) PFUs of RVFV ZH-501.

109 rafenib are important for the propagation of RVFV.

110 m by which sorafenib inhibits the release of RVFV virions from the cell.

111 e organization of G(C) in the outer shell of RVFV.

112 h viremias in livestock lead to spillover of RVFV into other anthrophillic vectors (Culex and Anophel

113 effective approach to prevent the spread of RVFV.

114 ort that an infection by the MP-12 strain of RVFV induces phosphorylation of the p65 component of the

115 decreased in cells infected with a strain of RVFV lacking the gene encoding the RVFV nonstructural pr

116 The crystal structure of RVFV G(C) reveals a class II fusion protein architecture

117 s that RVFV is pleomorphic, the structure of RVFV MP-12 was found to be highly ordered.

118 The 1.93-A crystal structure of RVFV N and electron micrographs of ribonucleoprotein (RN

119 tion regarding the genetic subpopulations of RVFV and shows the genetic stability of the MP-12 vaccin

120 R vesicles.IMPORTANCE In humans, symptoms of RVFV infection mainly include a self-limiting febrile il

121 Therefore, translation of RVFV mRNAs is compromised by multiple mechanisms during

122 mplications for fundamental understanding of RVFV virulence.

123 transcription, pointing to the uniqueness of RVFV NSs mRNA synthesis.

124 against ZH501, the fully virulent version of RVFV.

125 n be used to study the molecular virology of RVFV, assess current vaccine candidates, produce new vac

126 iruses were embedded within a large clade of RVFVs from the 2006-2007 outbreak in East Africa and sha

127 athrin-mediated endocytosis had no effect on RVFV infection.

128 cropinocytosis, had no significant impact on RVFV infection.

129 partially exerts its inhibitory influence on RVFV replication by interfering with IKK-beta2-mediated

130 MP-12 is the only RVFV strain excluded from the select-agent rule and hand

131 12 is different from its parental pathogenic RVFV strain, strain ZH548, because of the presence of 23

132 Rift Valley fever phlebovirus (RVFV) is a clinically and economically important pathoge

133 Preventing RVFV infection of livestock by vaccination is a key elem

134 fficacy of the DeltaNSs-DeltaNSm recombinant RVFV (rRVFV) vaccine (which lacks the NSs and NSm virule

135 ess this issue, we developed two recombinant RVFV vaccines using vaccinia virus (VACV) as a vector fo

136 Expression of DN caveolin-1 also reduced RVFV infection significantly, while expression of DN EPS

137 caveolin-1 and dynamin, drastically reduced RVFV infection in multiple cell lines.

138 skeletal reorganization, resulted in reduced RVFV replication, indicating that this pathway is import

139 ling as an important host pathway regulating RVFV infection.

140 In response, RVFV inhibits two well-known antiviral pathways that att

141 IFITM-2 and -3 restricted RVFV infection mostly by preventing virus membrane fusio

142 onal arrest of 5'-TOPs via 4EBP1/2 restricts RVFV replication, and this increased RNA decay results i

143 which target the TATA binding protein (TBP), RVFV appears to target the basal transcription factor TH

144 In contrast to previous assertions that RVFV is pleomorphic, the structure of RVFV MP-12 was fou

145 lts presented in this study demonstrate that RVFV MP-12 possesses T=12 icosahedral symmetry and sugge

146 Here we provide evidence that RVFV strain MP-12 uses dynamin-dependent caveola-mediate

147 Here, we find that RVFV infection triggers the decay of core translation ma

148 Our finding that RVFV NSs protein augmented minigenome RNA synthesis was

149 With further investigation, we found that RVFV infection activated Wnt signaling, was enhanced whe

150 Unexpectedly, we found that RVFV NSs truncated at aa.

151 etic screening in human cells and found that RVFV utilizes glycosaminoglycans to attach to host cells

152 We found that RVFV was restricted by IFITM-2 and -3 but not by IFITM-1

153 These results indicate that RVFV NSs induces DNA damage signaling pathways that are

154 ese data are consistent with the notion that RVFV outbreaks in Madagascar result not from emergence f

155 Our data point to the possibility that RVFV infection may result in the generation of novel ver

156 al minigenome RNA synthesis, suggesting that RVFV NSs protein and Bunyamwera virus NSs protein have d

157 The RVFV M segment encodes the NSm and 78-kDa proteins and t

158 strain of RVFV lacking the gene encoding the RVFV nonstructural protein S (NSs).

159 In addition, these results show how the RVFV incorporates a simple motif into the NSs protein th

160 family, replication and transcription of the RVFV minigenome required expression of viral N and L pro

161 alculated using the Fourier transform of the RVFV MP-12 tomogram.

162 f a recombinant subunit vaccine based on the RVFV Gn and Gc glycoproteins.

163 Consistent with the fact that the RVFV can be distinguished from other Bunyaviridae-family

164 These data suggest that the RVFV NSs protein is able to interact with the TFIIH subu

165 Infection of cells with the RVFV MP-12 vaccine strain reduced p62 protein levels to

166 e to the most recent common ancestor for the RVFVs.

167 V envelope glycoproteins, elicits high-titre RVFV-neutralizing antibody and provides solid protection

168 In contrast to RVFV, however, cellular transcription remains unaffected

169 ernative route of protective immunization to RVFV in addition to conventional intramuscular injection

170 In addition, disruption of PTAR1 led to RVFV resistance as well as reduced heparan sulfate surfa

171 nalyze the host transcriptome in response to RVFV infection.

172 CD4(+) T cells regulate immune responses to RVFV infection.

173 ellular helicases in type I IFN responses to RVFV.

174 y 42 of gestation, when fetal sensitivity to RVFV vaccine-induced teratogenesis is highest.

175 signs were noted and no macaque succumbed to RVFV infection.

176 Marmosets were more susceptible to RVFV than rhesus macaques and experienced higher rates o

177 re are no FDA-approved therapeutics to treat RVFV infection, and thus, there is an urgent need to und

178 er development of therapeutics used to treat RVFV infection.

179 might be an effective strategy for treating RVFV infection, which lacks approved vaccines and therap

180 Understanding RVFV-host interactions is imperative to the design of no

181 completely protected mice against a virulent RVFV challenge dose which was 100,000-fold greater than

182 lenged at day 122 of gestation with virulent RVFV (1.0 x 10(6) PFU intravenously).

183 ravenous and aerosol challenge with virulent RVFV in these macaques, which suggests further developme

184 Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) causes mo

185 Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) has a tri

186 Rift Valley fever virus (RVFV) (genus Phlebovirus, family Bunyaviridae) has a tri

187 ation of infectious Rift Valley fever virus (RVFV) and cowpox virus (CPXV) was also not affected by B

188 Rift Valley fever virus (RVFV) causes major outbreaks among livestock, characteri

189 Rift Valley fever virus (RVFV) causes outbreaks of severe disease in people and l

190 Rift Valley fever virus (RVFV) causes outbreaks of severe disease in people and l

191 Rift Valley fever virus (RVFV) causes recurrent insect-borne epizootics throughou

192 Rift Valley Fever virus (RVFV) causes recurrent outbreaks of acute life-threateni

193 Rift Valley fever virus (RVFV) has been expanding its geographical distribution w

194 Although the NSs of Rift Valley fever virus (RVFV) has been identified as an important virulence fact

195 Rift Valley fever virus (RVFV) is a highly pathogenic arthropod-borne virus infec

196 Rift Valley fever virus (RVFV) is a member of the Bunyaviridae virus family (genu

197 Rift Valley fever virus (RVFV) is a member of the genus Phlebovirus within the fa

198 Rift Valley fever virus (RVFV) is a mosquito-borne human and veterinary pathogen

199 Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing dise

200 Rift Valley fever virus (RVFV) is a negative-sense RNA virus (genus Phlebovirus,

201 Rift Valley fever virus (RVFV) is a single-stranded RNA virus capable of inducing

202 Rift Valley fever virus (RVFV) is a zoonotic pathogen capable of causing serious

203 Rift Valley fever virus (RVFV) is an arbovirus that is classified as a select age

204 Rift Valley fever virus (RVFV) is an arbovirus within the Bunyaviridae family cap

205 Rift Valley fever virus (RVFV) is an emerging pathogen that can cause severe dise

206 Rift Valley fever virus (RVFV) is an emerging RNA virus with devastating economic

207 nalysis of purified Rift Valley fever virus (RVFV) particles demonstrated the presence of three negat

208 f Cell, report that Rift Valley Fever Virus (RVFV) targets cellular transcriptional apparatus to inhi

209 e highly infectious Rift Valley fever virus (RVFV) that can be lethal to humans and animals and resul

210 nly modulated local Rift Valley fever virus (RVFV) transmission in ruminants.

211 Rift Valley fever virus (RVFV), a member in the Phlebovirus genus of the family B

212 Rift Valley fever virus (RVFV), a mosquito-borne phlebovirus, has been detected i

213 ring infection with Rift Valley fever virus (RVFV), a mosquito-borne virus that causes disease in hum

214 DX17 in restricting Rift Valley fever virus (RVFV), a mosquito-transmitted virus in the bunyavirus fa

215 Rift Valley fever virus (RVFV), an ambisense member of the family Bunyaviridae, g

216 Rift Valley fever virus (RVFV), belonging to the genus Phlebovirus, family Bunyav

217 Rift Valley fever virus (RVFV), belongs to genus Phlebovirus of the family Bunyav

218 smitted bunyavirus, Rift Valley fever virus (RVFV), is a highly successful pathogen for which there a

219 e family, including Rift Valley fever virus (RVFV), La Crosse virus, Andes virus, and Hantaan virus,

220 Rift Valley fever virus (RVFV), like many other Bunyaviridae family members, is a

221 gic fever caused by Rift Valley fever virus (RVFV), thus providing an animal model for RVFV pathogene

222 ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and

223 Rift Valley fever virus (RVFV), which belongs to the genus Phlebovirus, family Bu

224 nfections caused by Rift Valley fever virus (RVFV), which causes devastating disease in both humans a

225 ue virus (DENV) and Rift Valley fever virus (RVFV), which recently have seen significant progress in

226 ile virus (WNV) and Rift Valley fever virus (RVFV).

227 Rift Valley fever virus (RVFV, family Bunyaviridae, genus Phlebovirus) is a relev

228 Rift Valley fever virus (RVFV; family Bunyaviridae) is a clinically important, mo

229 Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus) has a trip

230 Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus) is an impo

231 RVF is caused by Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus), which has

232 tious viral disease caused by the RVF virus (RVFV) (Bunyaviridae: Phlebovirus), presents significant

233 The causative agent, RVF virus (RVFV), can be naturally transmitted by mosquito, direct

234 Rift Valley fever (RVF) virus (RVFV) can cause severe human disease characterized by ei

235 nlike N of other negative-sense RNA viruses, RVFV N has no positively charged surface cleft for RNA b

236 zing antibody responses that correlated with RVFV clearance from peripheral tissues.

237 on upon co-expression in cells infected with RVFV.

238 e as useful models of aerosol infection with RVFV.

239 except for intact NSs does not interact with RVFV NSs even in the presence of intact C-terminus self-

240 e of NSs, were protected from wild-type (wt) RVFV challenge, while 72% of mice vaccinated with MP-12